Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

NCT00394251 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00394251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00394251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2006
Completion date
February 1, 2008
Enrollment
197 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer